Inhibition by the CBP/β-catenin antagonist C-82/PRI-724 exerted potent activities against AML LICs and synergized with FLT3 inhibition in FLT3-mutant AML [64]. The gene discussed is FLT3; the disease is acute myeloid leukemia.